Author:
Lu Jian-Feng,Claret Laurent,Sutjandra Liviawati,Kuchimanchi Mita,Melara Rebeca,Bruno René,Sun Yu-Nien
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology
Reference19 articles.
1. Karrison TG, Maitland ML, Stadler WM, Ratain MJ (2007) Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer. J Natl Cancer Inst 99:1455–1461
2. Lavin PT (1981) An alternative model for the evaluation of antitumor activity. Cancer Clin Trials 4:451–457
3. Claret L, Andre V, Alwis D, Bruno R (2008) Modeling and simulation to assess the use of change in tumor size as primary endpoint in phase II studies in oncology [abstract 1386]. Presented at: Annual Meeting of the Population Approach Group in Europe. Marseille, France, June 18–20
4. Wang Y, Sung C, Dartois C, Ramchandani R, Booth BP, Rock E, Gobburu J (2009) Elucidation of relationship between tumor size and survival in non-small-cell lung cancer patients can aid early decision making in clinical drug development. Clin Pharmacol Ther 86:167–174
5. Bruno R, Claret L (2009) On the use of change in tumor size to predict survival in clinical oncology studies: toward a new paradigm to design and evaluate phase II studies. Clin Pharmacol Ther 86:136–138
Cited by
24 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献